Overblown Biomarkers: Are Publication, Funding Practices to Blame?
and meta-analyses when evaluating the evidence on biomarkers.”—Esther Landhuis None
ALL NEWS
378 RESULTS
You searched Esther
Sort By:
- Most Recent
- Most Commented
- Most Relevant
Lysosomal Block Clogs Transport, Swells Neurites
with blocked lysosomal proteolysis.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2803
Striatal Networks Go Haywire in Early Huntington’s Disease
news story).—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2799 Triplet Repeat
Making (Anti)sense of Rare Huntington’s Variant
in SCA7 and HD as well.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2798 Triplet Repeat
Patient-Derived Aβ Needs Prion Protein to Harm Synapses
antibodies, Rowan noted.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2797 Alzheimer's
ApoE Disrupts Brain Networks, Helps Microglia Clear Aβ
is hosting a one-day conference on May 24.—Esther Landhuis None
Gladstone Workshop: Tau and Tauopathies: Pathogenic Mechanisms
with Esther Landhuis's unfolding coverage of the San Francisco conference and her now-complete coverage
San Francisco: Tau—Time to Shine as Therapeutic Target?
the drill will penetrate the topic of synaptic pathophysiology in neurodegenerative disease.—Esther
San Francisco: Is Tau Reduction a Good Thing?
the idea that the shared gene set “sits neatly between amyloid and tau,” Lovestone said.—Esther Landhuis.
San Francisco: Making Tau Toxic—Post-translational Changes Galore
tau isoforms that appear in the brain (see review by Souter and Lee, 2010).—Esther Landhuis.
San Francisco: Gladstone Institute Hosts Tau Powwow
of post-translational modifications and interacting proteins. For more on these developments, read Part 2.—Esther
Lipid Modulator Offers New Route to BACE1 Inhibition
these possible side effects, Tomita said.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2778
Las Vegas: Can Collaboration Speed Drug Discovery for FTD?
with the Clinical Trials on Alzheimer’s Disease Conference, 3-5 November 2011 in San Diego.—Esther Landhuis.
Las Vegas: Are Frontotemporal Dementia Models Fit for Pharma?
in terms of recapitulating FTD phenotype,” Boxer told ARF.—Esther Landhuis. This is Part 2 of a three-part
Las Vegas: Lou Ruvo Center Pioneers New Approach to Clinical Trials
about that, see Part 2 and Part 3.—Esther Landhuis. This is Part 1 of a three-part series. See also Part